Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Oncoinvent AS

News headline image
Oncoinvent to Present at JonesTrading Virtual Radiopharma Day
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent to Present at Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent to Present at Evercore ISI 2024 Emerging Biotech Conference
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Ovarian Cancer Patients
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colorectal Cancer Patients
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Presents 15-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 2023 ASCO Annual Meeting
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Initiates Radspherin® Phase 2A Trial
From Oncoinvent AS
Via Business Wire
News headline image
Data From the Ongoing Radspherin® RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients to Be Presented at the 2022 ASCO Annual Meeting
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent to Participate in Upcoming Virtual Investor Conferences
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent appoints Adrian Senderowicz MD to its Board of Directors
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Announces Completion of Enrollment in the RAD-18-002 Phase 1 Clinical Study
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent to Present Four Posters at the 34th Annual Congress of the European Association of Nuclear Medicine
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Strengthens Leadership Team
From Oncoinvent AS
Via Business Wire
News headline image
Oncoinvent Announces Advancement of Radspherin® to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients
From Oncoinvent AS
Via Business Wire
News headline image
Following a Year of Outstanding Performance, Oncoinvent Aims to Raise NOK 150-200 Million to Move Into Efficacy Studies With Radspherin®
From Oncoinvent AS
Via Business Wire
News headline image
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® in the Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
From Oncoinvent AS
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.